past
two
decad
advanc
techniqu
bone
marrow
stem
cell
transplant
well
infecti
prophylaxi
support
care
improv
outcom
patient
hematolog
malign
condit
undergo
procedur
yet
overal
success
hematopoiet
cell
transplant
hct
lifeprolong
therapi
remain
limit
pulmonari
complic
signifi
cant
vex
sourc
morbid
mortal
purpos
chapter
provid
overview
epidemiolog
diagnost
consider
acut
pulmonari
complic
well
updat
review
specifi
c
diseas
entiti
clinic
situat
acut
respiratori
failur
occur
uniqu
popul
patient
complic
discuss
focu
primarili
observ
recipi
allogen
hct
context
chapter
term
acut
use
describ
pulmonari
complic
high
acuiti
would
requir
immedi
medic
attent
acut
care
set
result
acut
respiratori
failur
tradit
hctrelat
pulmonari
diseas
consid
context
time
frame
hct
complic
occur
within
fi
rst
day
often
categor
earlyonset
fi
rst
day
consid
lateonset
earlyonset
complic
tend
acut
present
directli
relat
lung
injuri
transplant
procedur
infect
associ
immun
reconstitut
statu
episod
acut
respiratori
failur
occur
earli
period
acut
respiratori
failur
occur
time
hct
day
noninfecti
pulmonari
diseas
predomin
spectrum
hctrelat
complic
manifest
lateonset
lung
injuri
chronic
graftversushost
diseas
patient
experi
acut
respiratori
failur
consequ
entiti
acut
infect
due
continu
immunosuppress
sever
pulmonari
syndrom
usual
occur
earli
posthct
period
occasion
caus
respiratori
compromis
longterm
survivor
outcom
respiratori
failur
contemporari
era
transplant
may
improv
due
reduc
incid
sever
lung
injuri
improv
prophylaxi
support
care
nonetheless
respiratori
failur
due
varieti
caus
continu
account
major
seriou
fatal
earli
complic
hct
approxim
hct
recipi
requir
icu
admiss
respiratori
failur
common
indic
histor
well
contemporari
practic
affect
hct
recipi
icu
acut
respiratori
failur
occur
frequent
allogen
recipi
compar
autolog
recipi
patient
highest
risk
acut
respiratori
failur
requir
mechan
ventil
includ
reduc
pretranspl
fev
undergon
myeloabl
condit
overal
prognosi
hct
recipi
experi
respiratori
failur
requir
mechan
support
poor
rubenfeld
crawford
propos
argument
withdraw
ventilatori
support
base
nest
casecontrol
studi
combin
lung
injuri
requir
mechan
ventil
elev
liver
function
enzym
renal
dysfunct
vasopressor
support
predict
death
messag
temper
fi
nding
overal
surviv
mechan
ventil
patient
improv
last
year
studi
took
place
year
sinc
infl
uential
articl
publish
nearli
year
ago
signifi
cant
advanc
icu
care
improv
surviv
critic
ill
patient
low
tidal
volum
ventil
strategi
endinspiratori
plateau
pressur
limit
reduc
barotrauma
lung
injuri
shown
decreas
mortal
adult
respiratori
distress
syndrom
ard
compar
convent
ventilatori
set
earli
goaldirect
therapi
sepsi
well
emphasi
prompt
empir
antibiot
administr
directli
impact
surviv
patient
sever
sepsi
circulatori
shock
addit
attent
support
care
measur
aspir
precaut
reduct
sedat
prevent
iatrogen
complic
like
contribut
improv
icu
outcom
hctspecifi
c
factor
nonmyeloabl
condit
regimen
becom
widespread
use
reduc
initi
toxic
incid
acut
gvhd
declin
due
prophylact
strategi
infecti
prophylaxi
decreas
incid
sever
earli
infecti
complic
sever
recent
studi
shown
modest
improv
outcom
hct
recipi
admit
icu
includ
requir
mechan
ventil
multicent
retrospect
studi
franc
icu
hospit
mortal
decreas
three
month
mortal
subgroup
requir
mechan
ventil
decreas
although
longer
consid
futil
mechan
ventil
remain
signifi
cant
independ
risk
factor
mortal
icu
associ
organ
dysfunct
includ
shock
liver
failur
also
remain
independ
predictor
death
differenti
diagnosi
acut
respiratori
failur
hct
broad
depend
time
onset
hct
fig
earli
hct
direct
noninfecti
complic
condit
procedur
includ
volum
overloadrel
pulmonari
edema
congest
heart
failur
sever
mucos
lead
aspir
pneumon
alway
consid
idiopath
pneumonia
syndrom
ip
preengraft
syndrom
diffus
alveolar
hemorrhag
dah
delay
pulmonari
toxic
syndrom
dpt
acut
fi
brinou
organ
pneumonia
afop
repres
form
lung
injuri
spectrum
histopatholog
fi
nding
specifi
c
transplant
procedur
etiolog
infecti
complic
relat
natur
degre
immunocompromis
patient
engraft
statu
pharmacolog
immunosuppress
noninfecti
etiolog
must
distinguish
infecti
complic
order
tailor
antimicrobi
therapi
guid
decis
empir
augment
immunosuppress
comput
tomographi
ct
chest
mandatori
initi
evalu
respiratori
failur
radiograph
pattern
may
suggest
specifi
c
etiolog
differenti
diagnosi
focal
diffus
infi
ltrate
broad
evalu
usual
undertaken
fiberopt
bronchoscopi
bronchoalveolar
lavag
bal
minim
invas
modal
reli
upon
make
specifi
c
diagnosi
new
onset
pulmonari
infi
ltrate
util
bronchoscopi
lie
exclus
infect
clinic
suspicion
noninfecti
etiolog
high
much
establish
specifi
c
infecti
etiolog
diagnost
yield
bal
improv
signifi
cantli
specifi
c
infecti
diagnos
due
advanc
diagnost
test
includ
cmv
rapid
shell
vial
cultur
aspergillu
galactomannan
respiratori
viral
pcr
panel
tabl
two
retrospect
studi
done
era
routin
antiinfect
prophylaxi
fungu
cmv
pneumocysti
jirovecii
report
yield
fi
beropt
bronchoscopi
specifi
c
diagnosi
higher
yield
allogen
hct
major
diagnos
achiev
bal
alon
transbronchi
biopsi
ad
addit
specifi
c
inform
case
aggress
diagnost
workup
appropri
hct
patient
impact
bal
patient
outcom
diffi
cult
ascertain
variou
factor
includ
time
procedur
may
infl
uenc
clinic
outcom
patient
often
refer
bal
persist
progress
diseas
empir
antibiot
therapi
larg
retrospect
studi
consecut
patient
underw
bal
evalu
new
pulmonari
infi
ltrate
suspect
pneumonia
fi
rst
day
hct
show
yield
bal
clinic
signifi
cant
pathogen
higher
p
perform
within
fi
rst
day
present
compar
perform
late
yield
highest
perform
within
h
present
mortal
day
follow
bal
signifi
cantli
lower
diagnosi
infect
confi
rmed
earli
bal
compar
late
bal
associ
multidrugresist
polymicrobi
infect
fi
nding
suggest
bal
use
earli
evalu
hct
recipi
pulmonari
infi
ltrate
oppos
conserv
expect
approach
bronchoscopi
failur
empir
therapi
use
bronchoscopi
larg
supplant
surgic
biopsi
mean
diagnos
unknown
lung
diseas
hct
patient
treatment
decis
depend
defi
nitiv
diagnosi
noninfecti
etiolog
empir
ther
api
riski
surgic
lung
biopsi
may
requir
achiev
specifi
c
diagnosi
case
pulmonari
venoocclus
diseas
pulmonari
cytolog
thrombi
exampl
surgic
lung
biopsi
advantag
direct
visual
biopsi
site
well
obtain
larg
enough
piec
tissu
allow
histolog
examin
cultur
bleed
set
thrombocytopenia
control
directli
contemporari
practic
surgic
lung
biopsi
usual
perform
videoscop
video
assist
thorac
surgeri
vat
theoret
reduc
morbid
associ
thoracotomi
lung
biopsi
popul
must
care
consid
morbid
surgeri
set
neutropenia
thrombocytopenia
andor
respiratori
failur
may
unaccept
high
particularli
overal
prognosi
poor
specifi
c
therapi
unlik
alter
outcom
white
colleagu
memori
sloan
ketter
cancer
center
contrast
classic
report
bone
marrow
transplant
recipi
prior
era
cmv
fungal
prophylaxi
infecti
etiolog
longer
common
diagnos
lung
biopsi
infl
ammatori
condit
common
specifi
c
diagnos
follow
infect
malign
likelihood
hct
recipi
undergo
surgic
lung
biopsi
continu
declin
past
two
decad
infecti
etiolog
lung
biopsi
particularli
invas
aspergillosi
signifi
cantli
less
like
noninfecti
etiolog
like
due
introduct
broad
spectrum
triazol
therapi
invas
fungal
infect
earli
recent
metaanalysi
show
overal
yield
specifi
c
diagnosi
similar
bal
surgeri
vs
complic
rate
bal
surgeri
respect
proport
noninfecti
diagnosi
exceed
infecti
diagnos
surgic
biopsi
spectrum
acut
lung
injuri
develop
earli
posttransplant
period
fall
categori
idiopath
pneumonia
syndrom
ip
includ
diffus
alveolar
hemorrhag
periengraft
syndrom
delay
pulmonari
toxic
syndrom
acut
fi
brinou
organ
pneumonia
tabl
broadli
defi
ned
widespread
alveolar
injuri
seen
hct
absenc
activ
lower
respiratori
tract
infect
cardiac
dysfunct
acut
renal
failur
iatrogen
fl
uid
overload
ip
thought
result
varieti
lung
insult
includ
toxic
effect
hct
condit
regimen
immunolog
cellmedi
injuri
infl
ammatori
cytokin
occult
pulmonari
infect
increas
use
new
diagnost
method
multiplex
pcr
respiratori
virus
biomark
galactomannan
aspergillu
spp
incid
acut
lung
injuri
secondari
pulmonari
infect
increas
seo
et
al
shown
approxim
half
patient
ip
pathogen
detect
bal
newer
diagnost
method
employ
pathogen
detect
associ
increas
mortal
frequent
pathogen
human
herp
human
rhinoviru
hrv
cytomegaloviru
cmv
aspergillu
spp
note
like
cmv
human
famili
latent
infect
healthi
adult
shown
reactiv
frequent
critic
ill
patient
specifi
c
role
pathogenesi
respiratori
diseas
outcom
critic
ill
remain
unknown
ip
classifi
ed
specifi
c
entiti
base
larg
part
presum
site
primari
tissu
injuri
primari
anatom
site
infl
ammat
dysfunct
divid
three
subtyp
pulmonari
parenchym
vascular
endotheli
airway
epitheli
subtyp
classifi
ed
distinct
entiti
noninfecti
acut
lung
injuri
ip
case
tabl
associ
ip
acut
gvhd
report
specifi
c
role
alloreact
donor
lymphocyt
pathogenesi
ip
remain
unclear
although
identifi
ed
lung
patient
ip
epitheli
apoptosi
consid
pathognomon
acut
gvhd
consist
detect
allogen
hct
recipi
acut
lung
dysfunct
pathognomon
histolog
fi
nding
defi
ne
ip
histolog
depend
upon
anatom
site
injuri
diagnosi
ip
rare
confi
rmed
tissu
biopsi
given
signifi
cant
risk
open
lung
biopsi
popul
low
yield
lung
tissu
transbronchi
biopsi
via
fi
beropt
bronchoscopi
recov
hct
patient
acut
lung
injuri
diagnosi
ip
usual
one
exclus
appropri
clinic
context
bal
often
perform
exclud
infect
cumul
incid
ip
allogen
hct
rang
follow
nonmyeloabl
condit
follow
convent
fullintens
radiat
contain
prepar
regimen
median
time
onset
allogen
hct
day
rang
day
mortal
rate
rang
overal
greater
patient
requir
mechan
ventil
although
ip
also
develop
autolog
hct
incid
lower
median
time
onset
gener
later
day
rang
day
respons
corticosteroid
usual
prompt
prognosi
favor
compar
ip
allogen
hct
recipi
risk
factor
ip
allogen
hct
includ
fullintens
condit
total
bodi
irradi
acut
gvhd
older
recipi
age
underli
diagnosi
acut
leukemia
myelodysplast
syndrom
number
platelet
transfus
administ
risk
factor
ip
follow
autolog
hct
includ
older
patient
age
sever
oral
mucos
condit
regimen
use
total
bodi
irradi
carmustin
bcnu
chest
irradi
within
week
transplant
femal
gender
underli
diagnosi
solid
tumor
current
standard
treatment
strategi
ip
includ
broadspectrum
antibiot
iv
corticosteroid
support
care
lung
protect
mechan
ventil
venoven
ultrafi
ltration
respiratori
failur
respons
corticosteroid
mgkgday
shown
mix
effi
caci
allogen
hct
recipi
like
refl
ect
divers
underli
caus
respons
lung
insult
compar
lower
dose
higher
dose
corticosteroid
therapi
mgkg
day
shown
improv
outcom
associ
increas
iatrogen
complic
includ
fungal
infect
prophylaxi
fi
lament
fungal
infect
voriconazol
micafungin
recommend
treatment
corticosteroid
mgkgday
fungal
pneumonia
identifi
ed
ip
patient
time
autopsi
singlecent
studi
preclin
clinic
studi
suggest
neutral
tumor
necrosi
factor
tnf
may
use
therapeut
strategi
ip
multicent
phase
ii
singlearm
openlabel
studi
yanik
colleagu
pediatr
hct
recipi
treatment
etanercept
mgkgdose
twice
weekli
dose
plu
corticosteroid
mgkgday
result
complet
respons
patient
associ
high
overal
surviv
compar
histor
control
random
doubleblind
placebocontrol
trial
corticosteroid
mgkgday
etanercept
mgkgdose
twice
weekli
dose
placebo
treatment
ip
use
corticosteroid
associ
higher
respons
rate
defi
ned
aliv
complet
discontinu
supplement
oxygen
support
day
initi
therapi
overal
surviv
compar
histor
control
addit
etanercept
lead
increas
respons
studi
truncat
earli
small
sampl
size
preclud
defi
nitiv
conclus
regard
benefi
etanercept
therapi
diffus
alveolar
hemorrhag
dah
also
call
acut
pulmonari
hemorrhag
hemorrhag
alveol
common
subset
ip
gener
develop
immedi
posttranspl
period
character
progress
dyspnea
cough
hypoxemia
without
fever
diffus
bilater
pulmonari
infi
ltrate
fig
cumul
incid
dah
hct
patient
median
time
onset
day
rang
day
allogen
recipi
day
rang
day
autolog
patient
diagnosi
base
progress
bloodier
return
bal
fl
uid
treatment
dah
consist
aggress
platelet
support
maintain
platelet
count
greater
equal
highdos
system
corticosteroid
mgkgday
gm
day
addit
aminocapro
acid
recombin
factor
vii
may
improv
outcom
despit
intervent
mortal
dah
rang
death
usual
due
multiorgan
failur
within
week
diagnosi
periengraft
respiratori
distress
syndrom
perd
develop
within
day
engraft
account
ip
case
allogen
hct
although
clinic
present
perd
hct
similar
subset
ip
lung
dysfunct
respons
corticosteroid
prognosi
better
incid
delay
pulmonari
toxic
syndrom
dpt
autolog
hct
recipi
receiv
chemotherapi
regimen
contain
bcnu
cyclophosphamid
cisplatin
median
time
onset
day
rang
day
treatment
corticosteroid
mgkgday
result
resolut
case
acut
fi
brinou
organ
pneumonia
afop
infrequ
observ
subset
ip
histolog
character
presenc
intraalveolar
fi
brin
form
fi
brin
ball
within
alveolar
space
organ
pneumonia
compos
intralumin
loos
connect
tissu
within
alveolar
duct
bronchiol
associ
fi
brin
type
ii
pneumocyt
hyperplasia
typic
patchi
distribut
afop
associ
varieti
diseas
state
includ
hct
infect
rheumatolog
diseas
well
environment
drug
exposur
present
symptom
may
includ
fever
cough
dyspnea
hemoptysi
malais
arthralgia
chest
pleural
abdomin
pain
two
distinct
clinic
cours
report
acut
fulmin
cours
typic
lead
respiratori
failur
death
less
sever
subacut
cours
radiograph
fi
nding
patient
acut
present
rapid
declin
similar
diffus
alveolar
damag
includ
diffus
basilar
predomin
consolid
ground
glass
opac
radiograph
featur
patient
subacut
afop
indistinguish
organ
pneumonia
focal
diffus
parenchym
abnorm
although
specifi
c
therapi
exist
case
report
describ
respons
corticosteroid
immunosuppress
therapi
cryptogen
organ
pneumonia
cop
origin
given
term
bronchiol
obliteran
organ
pneumonia
boop
fi
rst
describ
epler
distinct
clinicopatholog
entiti
affect
gener
popul
histolog
entiti
organ
pneumonia
op
may
associ
bacteri
viral
infect
op
gener
popul
idiopath
henc
term
cryptogen
organ
pneumonia
cop
hct
recipi
histolog
character
patchi
plug
granul
tissu
occupi
distal
termin
airway
alveolar
duct
alveolar
sac
widen
alveolar
septa
mononuclear
cell
infi
ltration
accumul
foami
macrophag
within
alveoli
fig
context
noninfecti
pulmonari
entiti
hct
cop
may
consid
lateonset
manifest
one
end
spectrum
lung
injuri
syndrom
ip
occupi
earli
onset
acut
end
spectrum
analysi
biopsyproven
case
cop
allogen
hct
signifi
cant
associ
presenc
acut
chronic
graftversushost
diseas
gvhd
multivari
analysi
note
sever
gvhd
acut
chronic
signifi
cantli
greater
patient
cop
compar
control
case
diagnos
set
corticosteroid
taper
gvhd
associ
sever
acut
gvhd
extens
chronic
gvhd
survivor
beyond
day
also
shown
larg
retrospect
studi
hct
recipi
japanes
registri
allogen
hct
recipi
risk
factor
shown
associ
cop
includ
donor
hla
dispar
femaletomal
hct
relat
peripher
blood
stem
cell
transplant
radiat
part
myeloabl
condit
regimen
although
alloimmun
mechan
may
postul
report
associ
gvhd
current
direct
evid
donor
tcellmedi
immun
respons
lung
tissu
entiti
clinic
present
cop
hct
similar
clinic
set
fever
cough
progress
dyspnea
aris
subacut
acut
tempo
median
time
onset
allogen
hct
recipi
approxim
month
transplant
although
mani
case
diagnos
day
longterm
survivor
sever
year
transplant
sinc
present
may
subacut
insidi
mani
patient
diagnos
outpati
set
diseas
progress
acut
respiratori
failur
necessit
ventil
support
aforement
case
seri
median
time
diagnosi
day
hct
rang
day
median
symptom
durat
day
pulmonari
function
test
may
reveal
new
restrict
defect
obstruct
defect
mix
restrict
obstruct
defect
normal
physiolog
sixtyfour
percent
new
diffus
capac
defi
cit
radiograph
hallmark
cop
chest
ct
ground
glass
opac
linear
opac
upper
lobe
often
bilater
distribut
fig
featur
biopsyproven
cop
chest
ct
includ
ground
glass
opac
consolid
linear
opac
upper
lobe
predomin
linear
opac
usual
describ
cop
occur
nonhct
set
radiograph
fi
nding
well
clinic
present
may
mimic
infecti
pneumonia
bronchoscopi
lavag
recommend
exclud
infecti
etiolog
case
clinic
diagnosi
still
unclear
histolog
diagnosi
surgic
lung
biopsi
may
warrant
mainstay
treatment
cop
hct
corticosteroid
usual
initi
dose
mgkgday
depend
sever
patient
sever
diseas
acut
respiratori
failur
administr
puls
steroid
g
initi
dose
justifi
ed
recent
recommend
suggest
treat
corticosteroid
start
mgkgday
symptomat
radiograph
improv
note
taper
slowli
minimum
month
although
littl
anecdot
evid
use
macrolid
popul
chronic
clarithromycin
azithromycin
may
ad
adjunct
immunomodulatori
agent
patient
diffi
culti
taper
toler
corticosteroid
overal
prognosi
cop
hct
good
major
case
resolv
stabil
corticosteroid
relaps
common
particularli
corticosteroid
taper
acceler
small
signifi
cant
proport
patient
progress
spite
therapi
ultim
succumb
respiratori
failur
refractori
case
hypothes
interstiti
infl
ammat
set
process
progress
interstiti
fi
brosi
evidenc
progress
interstiti
chang
comput
tomographi
known
factor
contribut
progress
individu
risk
progress
patient
surviv
past
day
allogen
hct
sens
amongst
transplant
physician
cop
increas
frequenc
true
incid
diffi
cult
ascertain
given
rel
rariti
condit
histolog
confi
rmation
lung
biopsi
rare
undertaken
investig
entiti
impact
hct
outcom
nonrelaps
mortal
warrant
bronchiol
obliteran
syndrom
bo
lateonset
chronic
pulmonari
problem
consid
acut
respiratori
failur
occur
set
rapid
airfl
ow
declin
infecti
complic
bo
character
new
onset
irrevers
airfl
ow
obstruct
set
prior
activ
chronic
graftversushost
diseas
usual
occur
within
fi
rst
year
hct
although
pathogenesi
bo
unknown
like
form
lung
injuri
caus
alloimmun
respons
airway
epithelium
aberr
repair
respons
result
obliter
small
airway
fi
brou
materi
lead
physiolog
correl
airway
obstruct
clinic
manifest
bo
usual
insidi
phenotyp
rapidli
progress
airfl
ow
obstruct
lead
primari
respiratori
failur
even
patient
bo
stabil
morbid
mortal
bo
high
result
mainli
infecti
pneumonia
progress
chronic
respiratori
failur
individu
compon
condit
regimen
use
hct
associ
pulmonari
toxic
carmustin
bischloroethylnitrosourea
bcnu
use
singl
agent
combin
prior
autolog
hct
solid
tumor
hematolog
malign
associ
acut
onset
pneumon
incid
prior
mediastin
radiat
therapi
bcnu
dose
greater
mg
age
less
independ
risk
factor
develop
pneumon
autolog
hct
lymphoma
mechan
bcnuassoci
pulmonari
toxic
entir
elucid
thought
includ
oxid
stress
glutathion
dysfunct
immunemedi
lung
injuri
cyclophosphamid
anoth
agent
use
combin
total
bodi
radiat
chemotherapi
agent
prepar
regimen
autolog
allogen
hct
associ
pulmonari
toxic
thought
relat
increas
reactiv
oxygen
speci
gener
deplet
glutathion
store
spectrum
druginduc
lung
diseas
report
transplant
associ
immunosuppress
therapi
implic
immunosuppress
agent
pattern
pulmonari
toxic
list
tabl
noncardiogen
pulmonari
edema
ard
report
associ
intraven
oral
cyclosporin
bone
marrow
transplant
resolv
medic
discontinu
postul
idiosyncrat
reaction
mammalian
target
rapamycin
mtor
inhibitor
sirolimu
bind
rapamycinfk
bind
inhibit
b
lymphocyt
prolifer
induct
long
term
mainten
immunosuppress
hct
use
acut
gvhd
prophylaxi
earli
posthct
period
primari
immunosuppress
activ
chronic
gvhd
pulmonari
toxic
rare
occur
sirolimu
context
may
sever
fatal
clinic
present
sirolimusinduc
lung
injuri
well
describ
solid
organ
transplant
popul
includ
cough
fatigu
fever
dyspnea
hemoptysi
physic
exam
note
hypoxemia
inspiratori
crackl
radiograph
fi
nding
ct
scan
includ
patchi
bilater
asymmetr
peripher
consolid
coplik
pattern
reticular
ground
glass
opac
lobar
consolid
bal
reveal
lymphocyt
eosinophil
alveol
case
predomin
histolog
pattern
organ
pneumonia
pulmonari
hemorrhag
diffus
alveolar
damag
minor
case
pulmonari
alveolar
proteinosi
mainstay
treatment
discontinu
drug
without
corticosteroid
mgkgday
result
complet
resolut
symptom
within
month
less
sever
case
manag
reduct
sirolimu
dose
close
monitor
serum
level
howev
relaps
report
approach
pulmonari
alveolar
proteinosi
pap
rare
diseas
character
accumul
surfact
lipid
protein
alveolar
space
result
ga
exchang
impair
primari
autoimmun
pap
due
presenc
autoantibodi
gmcsf
critic
regul
surfact
homeostasi
secondari
pap
compris
pap
case
occur
primarili
set
hematolog
malign
unusu
infect
eg
pneumocysti
jirovecii
nocardia
spp
underli
defect
thought
due
qualit
quantit
macrophag
dysfunct
defi
nition
autoantibodi
gmcsf
distinguish
primari
pap
context
hct
secondari
cryptogen
organ
pneumonia
diffus
alveolar
hemorrhag
interstiti
pneumon
laryng
edema
vascul
pap
extrem
rare
shown
autopsi
seri
caus
undiagnos
premortem
noninfecti
pulmonari
diseas
pap
report
follow
autolog
hct
cord
blood
transplant
cord
blood
transplant
associ
parainfl
uenza
viru
case
pap
resolv
chemotherapi
hct
underli
leukemia
presum
due
correct
quantit
defect
macrophag
present
marrowinfi
ltrate
diseas
process
patient
pap
risk
infect
may
also
confound
present
diagnosi
hct
recipi
primari
pap
secondari
pap
may
mild
selflimit
may
progress
respiratori
failur
patient
secondari
pap
present
progress
exert
dyspnea
nonproduct
cough
restrict
pattern
sever
reduc
diffus
capac
pulmonari
function
test
comput
tomographi
chest
show
diffus
patchi
ground
glass
opac
interlobular
thicken
subpleur
spare
crazi
pave
pattern
although
typic
primari
pap
bronchoscopi
reveal
milki
opaqu
lavag
fl
uid
contain
larg
foami
alveolar
macrophag
stain
posit
period
acidschiff
diagnost
appropri
clinic
set
bal
may
reveal
pa
materi
describ
recent
case
report
case
surgic
biopsi
show
pa
materi
architectur
preserv
alveolar
space
may
requir
confi
rm
diagnosi
therapi
secondari
pap
direct
underli
condit
ie
treatment
infect
malign
addit
support
care
corticosteroid
gener
ineffect
condit
mainstay
treatment
whole
lung
lavag
exogen
gmcsf
pap
hct
effect
cours
diseas
may
selflimit
venou
thromboembol
vte
underrecogn
complic
hct
retrospect
studi
hct
recipi
incid
symptomat
vte
within
fi
rst
day
post
transplant
includ
incid
noncatheterassoci
lower
extrem
dvt
incid
pulmonari
emboli
median
time
hct
admiss
develop
noncatheterassoci
lower
extrem
dvt
pulmonari
embol
day
respect
risk
factor
develop
vte
prior
vte
gvhd
thrombocytopenia
partial
protect
develop
vte
safeti
effi
caci
thromboprophylaxi
hct
patient
remain
uncertain
patient
thrombocytopenia
anticoagul
therapi
document
vte
accompani
platelet
transfus
maintain
platelet
count
l
greater
reduc
risk
bleed
complic
pulmonari
venoocclus
diseas
pvod
rare
lateonset
complic
hct
present
insidi
onset
fatigu
exert
dyspnea
within
month
transplant
physic
examin
typic
show
hypoxemia
rest
tachycardia
consist
pulmonari
hypertens
right
heart
catheter
demonstr
elev
pulmonari
arteri
pressur
normal
pulmonari
capillari
wedg
pressur
angiographi
use
exclud
pulmonari
emboli
etiolog
pulmonari
hypertens
diagnosi
pvod
strongli
support
triad
pulmonari
arteri
hypertens
radiograph
evid
pulmonari
edema
normal
pulmonari
arteri
occlus
pressur
howev
lung
biopsi
confi
rm
diagnosi
presenc
extens
diffus
intim
prolifer
fi
brosi
pulmonari
venul
treatment
consist
highdos
corticosteroid
methylprednisolon
mgkgday
anecdot
success
overal
prognosi
pvod
hct
remain
poor
pulmonari
cytolyt
thrombu
pct
seen
exclus
allogen
hct
recipi
almost
alway
children
incid
pct
report
rang
median
onset
month
rang
month
transplant
clinic
manifest
includ
fever
cough
respiratori
distress
ct
fi
nding
rang
small
peripher
nodul
diffus
opac
diagnosi
requir
lung
biopsi
histolog
character
vascular
occlus
distal
pulmonari
vessel
entrap
leukocyt
endotheli
disrupt
infarct
adjac
tissu
singlecent
retrospect
studi
grade
ii
iv
acut
chronic
gvhd
independ
risk
factor
develop
pct
treatment
pct
consist
system
corticosteroid
prednison
mg
kgday
pulmonari
symptom
resolv
typic
within
week
follow
steroid
taper
week
strong
associ
acut
chronic
gvhd
well
respons
corticosteroid
therapi
suggest
pct
manifest
alloreact
lung
injuri
prognosi
pct
favor
report
death
attribut
entiti
profound
alter
immun
statu
associ
bone
marrow
stem
cell
transplant
render
popul
vulner
sever
opportunist
communityacquir
pneumonia
precipit
acut
respiratori
failur
fig
fi
rst
month
hct
neutropenia
immun
suppress
manag
acut
earli
gvhd
contribut
infect
risk
predominantli
due
bacteri
pneumonia
nosocomi
gramposit
gramneg
organ
herp
simplex
viru
candida
speci
earli
postengraft
phase
month
posthct
character
impair
cellular
immun
continu
immun
suppress
gvhd
interrupt
prophylaxi
opportunist
viral
fungal
infect
predomin
late
postengraft
phase
immunosuppress
therapi
decreas
patient
pulmonari
infect
due
commonli
communityacquir
organ
opportunist
pathogen
hct
recipi
particularli
vulner
uncommon
pathogen
suffer
sever
manifest
common
pathogen
much
learn
particular
agent
come
experi
popul
section
focu
review
import
viral
fungal
pathogen
affect
hct
recipi
contemporari
era
although
specifi
c
antivir
therapi
preemptiv
treatment
strategi
reduc
impact
cytomegaloviru
cmv
pneumonia
earli
posttranspl
period
cmv
remain
import
opportunist
viral
pathogen
caus
acut
respiratori
diseas
mortal
hct
recipi
prior
implement
cmv
prophylaxi
late
incid
cmv
pneumonia
allogen
hct
autolog
recipi
use
ganciclovir
prophylaxi
earli
posttranspl
period
decreas
overal
incid
increas
proport
diseas
occur
late
transplant
period
day
risk
factor
develop
late
onset
diseas
includ
cmv
antigenemia
fi
rst
month
delay
lymphocyt
engraft
low
count
acut
graftversushost
diseas
singl
center
retrospect
review
case
cmv
pneumonia
year
span
overal
surviv
hct
recipi
cmv
pneumonia
onset
approxim
treatment
iv
ganciclovir
foscarnet
associ
decreas
overal
mortal
patient
cmv
pneumonia
time
surprisingli
coinfect
lung
pathogen
associ
increas
overal
mortal
lymphopenia
use
mechan
ventil
time
cmv
onset
independ
associ
increas
risk
cmvattribut
mortal
diagnosi
cmv
pneumonia
requir
evid
viru
cultur
cytolog
immunohistochemistri
polymeras
chain
reaction
pcr
direct
fl
uoresc
antibodi
method
bal
fl
uid
lung
biopsi
conjunct
bilater
infi
ltrate
chest
imag
use
rapid
detect
cmv
shell
vial
cultur
highli
sensit
method
detect
cmv
improv
util
bronchoscopi
make
diagnosi
quantit
pcr
bal
may
higher
sensit
cmv
use
mani
center
howev
lack
appropri
cutoff
viral
load
limit
interpret
posit
result
presenc
intranuclear
inclus
lung
biopsi
confi
rm
presenc
cmv
pneumonia
lung
biopsi
rare
requir
achiev
diagnosi
major
patient
cmv
pneumonia
evid
cmv
reactiv
blood
first
line
antivir
therapi
cmv
diseas
iv
ganciclovir
nucleosid
analog
inhibit
dna
synthesi
induct
phase
day
follow
least
week
mainten
therapi
major
side
effect
ganciclovir
neutropenia
limit
use
preengraft
phase
highdos
intraven
pool
immunoglobulin
cmvspecifi
c
immunoglobulin
administ
adjunct
iv
ganciclovir
standard
care
mani
year
base
earli
open
label
trial
recent
analys
show
effect
attribut
mortal
foscarnet
inhibit
cmv
viral
polymeras
second
line
therapi
patient
known
resist
ganciclovir
major
side
effect
nephrotox
third
line
therapi
cidofovir
competit
inhibitor
dna
polymeras
signifi
cant
renal
hematolog
toxic
antivir
prophylaxi
gancyclovir
shown
clinic
trial
reduc
burden
diseas
earli
transplant
cost
prolong
neutropenia
increas
bacteri
fungal
infect
well
select
ganciclovirresist
strain
cmv
institut
use
preemptiv
strategi
patient
show
evid
cmv
reactiv
blood
antigenemia
viral
load
weekli
screen
treat
ganciclovir
decreas
risk
cmv
pneumonia
commun
respiratori
virus
crv
caus
consider
morbid
mortal
immunocompromis
popul
upper
respiratori
tract
ill
progress
lower
tract
diseas
acut
respiratori
failur
risk
factor
progress
pneumonia
hct
recipi
includ
infect
earli
transplant
allogen
hct
myeloabl
condit
gvhd
lymphopenia
major
clinic
relev
crv
diagnos
nasal
wash
nasopharyng
swab
bal
rapid
antigen
detect
rtpcr
method
specifi
c
antivir
agent
effi
caci
crv
manag
primarili
support
hct
recipi
may
shed
viru
prolong
period
time
crv
includ
infl
uenza
respiratori
syncyti
viru
rsv
parainfl
uenza
peak
primarili
winter
month
parainfl
uenza
adenoviru
occur
year
round
pattern
infl
uenza
infect
hct
recipi
refl
ect
season
occurr
commun
incid
season
infl
uenza
infect
hct
mortal
rate
set
pneumonia
due
preval
resist
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamavir
zanamivir
use
immunosuppress
host
suspect
document
infl
uenza
parainfl
uenza
viru
major
caus
laryngotracheobronch
children
parainfl
uenza
frequent
found
immunocompromis
patient
almost
half
hct
recipi
piv
infect
progress
lower
respiratori
tract
infect
mortal
rate
although
sometim
use
ribarivin
ivig
shown
effi
caciou
treat
piv
pneumonia
novel
sialidas
fusion
protein
current
test
clinic
trial
treat
piv
diseas
sever
immunocompromis
individu
newli
discov
respiratori
virus
clinic
signifi
canc
emerg
within
past
decad
includ
human
metapneumoviru
hmpv
human
bocaviru
new
coronavirus
hmpv
fi
rst
report
associ
mortal
lower
respiratori
tract
diseas
hmpv
detect
hct
recipi
fulmin
respiratori
failur
initi
attribut
ip
respiratori
syncyti
viru
rsv
one
lead
caus
viral
pneumonia
hct
recipi
affect
hct
recipi
document
respiratori
viral
infect
usual
present
upper
respiratori
tract
infect
rhinorrhea
sinu
congest
sore
throat
rsv
infect
progress
bronchiol
pneumon
pneumonia
patient
yet
engraft
highest
risk
progress
lower
tract
diseas
pneumonia
establish
mortal
risk
factor
mortal
includ
hypoxemia
steroid
time
diagnosi
mechan
ventil
survivor
hct
lower
respiratori
tract
infect
rsv
fi
rst
day
associ
increas
risk
develop
airfl
ow
declin
may
recogn
bo
uncontrol
studi
suggest
treatment
rsv
lower
respiratori
tract
infect
aerosol
ribavirin
rsvig
reduc
mortal
initi
onset
respiratori
failur
novel
compound
rsv
entri
inhibitor
reduc
viral
load
sever
clinic
diseas
healthi
adult
volunt
current
phase
ii
clinic
trial
treat
rsv
hct
recipi
epidemiolog
invas
fungal
infect
ifi
continu
evolv
advanc
detect
prophylaxi
treatment
recent
revis
defi
nition
proven
probabl
invas
fungal
diseas
appli
incid
ifi
allogen
hct
recipi
aspergillosi
account
ifi
follow
candidiasi
mucormycosi
widespread
use
voriconazol
may
contribut
emerg
mold
infect
decreas
suscept
voriconazol
includ
mucoral
spp
manifest
aspergillu
hct
popul
includ
airway
colon
tracheobronch
pneumonia
sinus
dissemin
diseas
symptom
pulmonari
invas
aspergillosi
ia
includ
dyspnea
fever
product
cough
chest
pain
hemoptysi
patient
may
also
asymptomat
recoveri
neutropenia
allogen
hct
recipi
invas
fi
lament
fungal
infect
present
dyspnea
febril
mortal
month
time
ia
diagnosi
rang
autolog
recipi
unrel
donor
recipi
differ
earlyversu
lateonset
infect
gold
standard
diagnosi
ia
biopsi
cultur
set
compat
clinic
radiograph
featur
howev
biopsi
rare
perform
confi
rm
ia
galactomannan
fungal
polysaccharid
specifi
c
aspergillu
spp
wide
use
biomark
detect
ia
serum
bal
fl
uid
serum
galactomannan
assay
sensit
specifi
citi
respect
detect
ia
hct
recipi
galactomannan
test
bal
sensit
specifi
citi
pcrbase
method
detect
aspergillu
yet
standard
clinic
use
although
publish
studi
indic
bal
analysi
use
quantit
rtpcr
sensit
specifi
citi
approach
treatment
ia
involv
reduc
level
immunosuppress
extent
possibl
addit
use
antifung
agent
appropri
effi
caci
minim
toxic
profi
le
import
recogn
clinic
relev
azol
antimicrobi
inhibit
cytochrom
isoenzym
activ
vari
degre
result
increas
serum
concentr
cyclosporin
tacrolimu
sirolimu
everolimu
could
lead
neurotox
andor
nephrotox
medic
must
doseadjust
patient
requir
azol
treatment
ifi
voriconazol
broadspectrum
triazol
deriv
becam
avail
agent
choic
treatment
ia
base
superior
effi
caci
surviv
benefi
comparison
amphotericin
liposom
amphotericin
b
altern
patient
azol
intoler
echinocandin
caspofungin
micafungin
anidulafungin
also
option
treatment
ia
low
potenti
drug
interact
although
tacrolimu
level
may
reduc
surgic
resect
focal
invas
diseas
refractori
medic
therapi
consid
neutropen
patient
inhal
liposom
amphotericin
b
addit
system
antifung
use
treatment
fungal
tracheobronch
mucormycosi
aggress
infect
high
mortal
associ
prolong
neutropenia
account
ifi
hct
recipi
often
late
complic
month
transplant
pulmonari
involv
half
case
overal
mortal
rate
among
hct
recipi
least
first
line
therapi
liposom
amphotericin
b
least
week
extens
earli
surgic
debrid
combin
liposom
amphotericin
echinocandin
may
consid
case
refractori
fi
rst
line
therapi
isavuconazol
promis
new
extend
spectrum
triazol
excel
oral
bioavail
low
side
effect
profi
le
may
util
primari
therapi
invas
mucormycosi
ifi
acut
respiratori
diseas
signifi
cant
contributor
morbid
mortal
hematopoiet
cell
transplant
differenti
diagnosi
pulmonari
diseas
depend
time
frame
hct
patient
immun
statu
spectrum
noninfecti
acut
lung
injuri
develop
earli
posttransplant
period
fall
categori
idiopath
pneumonia
syndrom
ip
lateonset
lung
injuri
usual
manifest
cryptogen
organ
pneumonia
noninfecti
pulmonari
complic
includ
pulmonari
alveolar
proteinosi
pulmonari
vascular
diseas
drug
toxic
epidemiolog
acut
lung
injuri
classic
infecti
etiolog
acut
respiratori
diseas
popul
chang
sinc
advent
improv
support
care
diagnost
detect
treatment
